New agents targeting endocrine therapy and CDK4/6 resistance in hormone receptor–positive breast cancer are in development.

Targeted alpha therapy shows promise in treating neuroendocrine tumours, offering hope where beta therapies fall short.

A research team led by Prof. Liu Chenli from the Shenzhen Institutes of Advanced Technology of the Chinese Academy of Sciences (CAS) and Prof. Xiao Yichuan from the Shanghai Institute of Nutrition and ...

A research team has elucidated the mechanism behind bacterial cancer therapy using a genetically engineered bacterial strain. Their findings were published in Cell. Exploring the use of antitumor ...

Lupron and other LHRH agonists are forms of hormone-blocking therapy. For people with prostate cancer, hormone-blocking therapy aims to reduce testosterone levels in the body. Male hormones ...

A review in Brain Medicine unveils the potential of targeted alpha particle therapy (TAT) as an innovative and exciting ...

In a comprehensive Genomic Press Viewpoint (review) article, researchers are shining a spotlight on a revolutionary approach to tackling neuroendocrine tumors (NETs), a rare but increasingly prevalent ...

"Endocrine therapy is typically used in the initial treatment of HR-positive metastatic breast cancer but as the disease progresses, the benefit of continued endocrine therapy is limited ...